[feed] Atom [feed] RSS 1.0 [feed] RSS 2.0

Raychaudhuri, D and Raychaudhuri, R and Sinha , BP and Liu , SC and Ghosh, AR and Rahaman , O and Bandopadhyay, P and Sarif, J and D'Rozario, R and Paul , S and Das, A and Sarkar, DK and Chattopadhyay , S and Ganguly, D (2019) Lactate Induces Pro-tumor Reprogramming in Intratumoral Plasmacytoid Dendritic Cells. Front Immunol (10). p. 1878.

[img] Text
51.Dr. Samit C. (Front Imm) open access.pdf
Restricted to Repository staff only

Download (4Mb) | Request a copy

Abstract

Plasmacytoid dendritic cells are the most efficient producers of type I interferons, viz. IFNα, in the body and thus have the ability to influence anti-tumor immune responses. But repression of effective intra-tumoral pDC activation is a key immuno-evasion strategy exhibited in tumors-tumor-recruited pDCs are rendered "tolerogenic," characterized by deficiency in IFNα induction and ability to expand regulatory T cells in situ. But the tumor-derived factors that drive this functional reprogramming of intra-tumoral pDCs are not established. In this study we aimed at exploring if intra-tumoral abundance of the oncometabolite lactate influences intra-tumoral pDC function. We found that lactate attenuates IFNα induction by pDCs mediated by intracellular Ca2+ mobilization triggered by cell surface GPR81 receptor as well as directly by cytosolic import of lactate in pDCs through the cell surface monocarboxylate transporters, affecting cellular metabolism needed for effective pDC activation. We also found that lactate enhances tryptophan metabolism and kynurenine production by pDCs which contribute to induction of FoxP3+ CD4+ regulatory T cells, the major immunosuppressive immune cell subset in tumor microenvironment. We validated these mechanisms of lactate-driven pDC reprogramming by looking into tumor recruited pDCs isolated from patients with breast cancers as well as in a preclinical model of breast cancer in mice. Thus, we discovered a hitherto unknown link between intra-tumoral abundance of an oncometabolite resulting from metabolic adaptation in cancer cells and the pro-tumor tolerogenic function of tumor-recruited pDCs, revealing new therapeutic targets for potentiating anti-cancer immune responses.

Item Type: Article
Subjects: Infection and Immunity
Depositing User: Mr. Rameshwar Nema
Date Deposited: 30 Aug 2020 09:00
Last Modified: 08 Dec 2021 11:06
URI: http://nccs.sciencecentral.in/id/eprint/817

Actions (login required)

View Item View Item